This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Berger, A. C. Articles by Hoffman, J. P. Search for Related Content PubMed PubMed Citation Articles by Berger, A. C. Articles by Hoffman, J. P.

Undetectable Preoperative Levels of Serum CA 19-9 Correlate with Improved Survival for Patients with Resectable Pancreatic Adenocarcinoma

From the Departments of Surgical Oncology (ACB, IMM, JCW, JPH) and Biostatistics (EAR), Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Correspondence: Address correspondence and reprint requests to: Adam C. Berger, MD, Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111; Fax: 215-728-2773; E-mail: a_berger{at}fccc.edu

Background: Serum levels of CA19-9 have been shown to correlate with both recurrence and survival in patients with pancreatic cancer. However, little is known about the prognosis for patients with undetectable levels of serum CA19-9.

Methods: One hundred twenty-nine patients with pancreatic cancer who underwent preoperative assessment of serum CA19-9 followed by resection with curative intent between 1990 and 2002 were retrospectively analyzed. Data collected included preoperative serum CA19-9 level (U/mL), age, pathologic staging, and survival. Data were analyzed with the SAS system according to four distinct preoperative serum CA19-9 levels: undetectable, normal (<37), 38–200, and >200 U/mL.

Results: Serum CA19-9 levels ranged from undetectable to 16,300 U/mL. Stage III/IV disease accounted for 86%, 67%, 59%, and 53% of patients in the four CA19-9 groups. The overall median and 5-year survivals were 19 months and 11%, respectively. Survival was similar between nonsecretors and those with normal CA 19-9 levels. However, both groups had statistically significant prolonged survival compared with the two groups with elevated CA 19-9 levels (P = .003). The only factors that were significant on univariate and multivariate analysis for overall survival were lymph node positivity (P = .015 and .002) and CA 19-9 grouping (P = .003 and P < .0001). Although this group of patients presented with predominately advanced-stage disease, their overall survival was superior.

Conclusions: These findings suggest that patients who present with undetectable preoperative CA19-9 levels and potentially resectable pancreatic cancer, regardless of advanced stage, should be considered candidates for aggressive therapy.

Key Words: CA 19-9 • Lewis blood group • Pancreatic cancer • Prognosis

This article has been cited by other articles:

				C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau, S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren, et al. Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent Cancer Res., March 15, 2008; 68(6): 1970 - 1978. [Abstract] [Full Text] [PDF]

				C. R. Ferrone, D. M. Finkelstein, S. P. Thayer, A. Muzikansky, C. F.-d. Castillo, and A. L. Warshaw Perioperative CA19-9 Levels Can Predict Stage and Survival in Patients With Resectable Pancreatic Adenocarcinoma J. Clin. Oncol., June 20, 2006; 24(18): 2897 - 2902. [Abstract] [Full Text] [PDF]

				M. Bouvet Editorial: Tumor Markers for Pancreatic Cancer: What Happens When Preoperative CA 19-9 is Undetectable? Ann. Surg. Oncol., July 1, 2004; 11(7): 637 - 638. [Full Text] [PDF]